A former Sanofi I&I development executive has brought together a who’s who of investors and assembled three drug candidates from Chinese and US biotechs after scanning about 100 global assets.
Frédéric Marrache, who spent much of the past decade at the French pharma leading clinical work on immunology and inflammation, has collected $165 million as a first-time CEO to build out a pipeline of experimental medicines for conditions including IBD and eczema.